Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observer-blind, Multi-center, Placebo-controlled, Parallel Group Study to Assess the Safety and Tolerability and to Characterize the Pharmacokinetics and the Pharmacodynamics of Different Doses of BAY1213790 in Patients With End-stage Renal Disease Undergoing Hemodialysis

NCT03787368 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03787368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03787368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observer-blind, Multi-center, Placebo-controlled, Parallel Group Study to Assess the Safety and Tolerability and to Characterize the Pharmacokinetics and the Pharmacodynamics of Different Doses of BAY1213790 in Patients With End-stage Renal Disease Undergoing Hemodialysis
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2019
Completion date
September 15, 2021
Enrollment
55 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

renal dialysis